INTS Logo

Intensity Therapeutics, Inc. - Common Stock (INTS) Stock Forecast & Price Prediction

Live INTS Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$2.32

+0.06 (2.52%)

12 Month Price Forecast For INTS

$2.32
Current Price
$34.19M
Market Cap
4 Ratings
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to INTS Price Forecasts

+589.7%
To High Target of $16.00
+331.0%
To Median Target of $10.00
+72.4%
To Low Target of $4.00

INTS Price Momentum

+2.7%
1 Week Change
+7.9%
1 Month Change
-35.6%
1 Year Change
+31.8%
Year-to-Date Change
-60.9%
From 52W High of $5.94
+54.7%
From 52W Low of $1.50

๐Ÿค” Considering Intensity Therapeutics (INTS)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 3:40 AM UTC

INTS Analyst Ratings & Price Targets

Based on our analysis of 3 Wall Street analysts, INTS has a bullish consensus with a median price target of $10.00 (ranging from $4.00 to $16.00). Currently trading at $2.32, the median forecast implies a 331.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

INTS Analyst Consensus

4
Buy
0
Hold
0
Sell

INTS Price Target Range

Low
$4.00
Average
$10.00
High
$16.00
Current: $2.32

Latest INTS Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for INTS.

Date Firm Analyst Rating Change Price Target
Jan 13, 2025 Alliance Global Partners James Molloy Buy Initiates $8.50
Nov 21, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Reiterates $5.00
Oct 31, 2024 HC Wainwright & Co. Swayampakula Ramakanth Buy Initiates $5.00
Jul 11, 2024 Benchmark Robert Wasserman Speculative Buy Reiterates $12.00
May 16, 2024 Benchmark Robert Wasserman Speculative Buy Reiterates $12.00
Mar 21, 2024 Benchmark Robert Wasserman Speculative Buy Reiterates $12.00
Nov 14, 2023 Benchmark Robert Wasserman Speculative Buy Reiterates $12.00
Aug 24, 2023 Benchmark Robert Wasserman Speculative Buy Reiterates $12.00
Jul 18, 2023 Benchmark Robert Wasserman Speculative Buy Initiates $12.00

Stocks Similar to Intensity Therapeutics, Inc. - Common Stock

The following stocks are similar to Intensity Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Intensity Therapeutics, Inc. - Common Stock (INTS) Financial Data

Intensity Therapeutics, Inc. - Common Stock has a market capitalization of $34.19M with a P/E ratio of -1.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -147.2%.

Valuation Metrics

Market Cap $34.19M
Enterprise Value $37.55M
P/E Ratio -1.7x
PEG Ratio -1.9x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +19.8%
Current Ratio 2.3x
Debt/Equity 2.8x
ROE -147.2%
ROA -72.7%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Intensity Therapeutics, Inc. - Common Stock logo

Intensity Therapeutics, Inc. - Common Stock (INTS) Company Overview

About Intensity Therapeutics, Inc. - Common Stock

What They Do

Develops innovative cancer treatment therapies.

Business Model

The company focuses on discovering and developing cancer drugs, primarily targeting refractory solid tumors. It generates revenue through the advancement of its lead product candidate, INT230-6, which is currently undergoing various phases of clinical trials.

Additional Information

Intensity Therapeutics, Inc. was founded in 2012 and is headquartered in Shelton, Connecticut, positioning itself within the clinical-stage biotechnology sector in the United States.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

5

CEO

Mr. Lewis H. Bender M.A., M.B.A., M.S.

Country

United States

IPO Year

2022

Intensity Therapeutics, Inc. - Common Stock (INTS) Latest News & Analysis

INTS stock latest news image
Quick Summary

Intensity Therapeutics' Phase 3 INVINCIBLE-3 study for sarcoma therapies continues recruitment, with approvals in the U.S., Canada, Europe, and Australia. The study will proceed without changes.

Why It Matters

The continuation of the INVINCIBLE-3 Study without modifications signals confidence in Intensity Therapeutics' cancer treatment, potentially boosting investor sentiment and stock performance.

Source: PRNewsWire
Market Sentiment: Neutral
INTS stock latest news image
Quick Summary

Intensity Therapeutics has received regulatory approvals for its Phase 3 study on metastatic soft tissue sarcoma and is conducting a Phase 2 trial for triple-negative breast cancer in Switzerland.

Why It Matters

Regulatory approvals for clinical studies enhance Intensity Therapeutics' credibility and potential for breakthroughs in cancer treatment, impacting stock performance and investor sentiment.

Source: PRNewsWire
Market Sentiment: Neutral
INTS stock latest news image
Quick Summary

Intensity Therapeutics has activated seven clinical trial sites in Switzerland for its novel intratumoral cancer therapies. Enrollment is currently ongoing.

Why It Matters

The activation of seven clinical trial sites in Switzerland signals progress for Intensity Therapeutics, potentially boosting its stock value and attracting investor interest in its cancer therapies.

Source: PRNewsWire
Market Sentiment: Neutral
INTS stock latest news image
Quick Summary

Intensity Therapeutics has signed a securities purchase agreement to sell 1,237,113 shares of common stock at $2.425 per share to a healthcare-focused institutional investor.

Why It Matters

Intensity Therapeutics' securities purchase agreement signals investor interest and funding for its cancer therapies, potentially impacting stock performance and future growth prospects.

Source: PRNewsWire
Market Sentiment: Neutral
INTS stock latest news image
Quick Summary

Phase 1/2 data for INT230-6 showed a median overall survival of 21.3 months, compared to 6.7 months in synthetic controls. The INVINCIBLE-3 Study is recruiting 333 patients across several countries.

Why It Matters

Positive survival data and strong safety profiles for INT230-6 could boost Intensity Therapeutics' stock value, attract investment interest, and enhance its market position in cancer therapies.

Source: PRNewsWire
Market Sentiment: Neutral
INTS stock latest news image
Quick Summary

Intensity Therapeutics has dosed the first patient in a Phase 2 study for presurgical triple negative breast cancer. The company also announced its Q3 2024 financial results.

Why It Matters

The initiation of a Phase 2 study signals progress in Intensity's drug development, potentially boosting investor confidence and impacting stock performance in the biotechnology sector.

Source: PRNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About INTS Stock

What is Intensity Therapeutics, Inc. - Common Stock's (INTS) stock forecast for 2025?

Based on our analysis of 3 Wall Street analysts, Intensity Therapeutics, Inc. - Common Stock (INTS) has a median price target of $10.00. The highest price target is $16.00 and the lowest is $4.00.

Is INTS stock a good investment in 2025?

According to current analyst ratings, INTS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.32. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for INTS stock?

Wall Street analysts predict INTS stock could reach $10.00 in the next 12 months. This represents a 331.0% increase from the current price of $2.32. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Intensity Therapeutics, Inc. - Common Stock's business model?

The company focuses on discovering and developing cancer drugs, primarily targeting refractory solid tumors. It generates revenue through the advancement of its lead product candidate, INT230-6, which is currently undergoing various phases of clinical trials.

What is the highest forecasted price for INTS Intensity Therapeutics, Inc. - Common Stock?

The highest price target for INTS is $16.00 from at , which represents a 589.7% increase from the current price of $2.32.

What is the lowest forecasted price for INTS Intensity Therapeutics, Inc. - Common Stock?

The lowest price target for INTS is $4.00 from at , which represents a 72.4% increase from the current price of $2.32.

What is the overall INTS consensus from analysts for Intensity Therapeutics, Inc. - Common Stock?

The overall analyst consensus for INTS is bullish. Out of 3 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.

How accurate are INTS stock price projections?

Stock price projections, including those for Intensity Therapeutics, Inc. - Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.